sub:assertion { d:DB06097v:identifier "DB06097" ; v:namespace "drugbank" ; v:uri "http://bio2rdf.org/drugbank:DB06097" ; v:x-identifiers.org <http://identifiers.org/drugbank/DB06097> ; dv:drugbank-id "DB06097" ; dv:x-cas <http://bio2rdf.org/cas:> ; dct:description "GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline (GSK). GSK-923295 demonstrated a broad spectrum of activity against a range of human tumor xenografts grown in nude mice, including models of colon, breast, ovarian, lung and other tumors. GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK."@en ; dct:identifier "drugbank:DB06097" ; dct:title "GSK-923295"@en ; adv:Drug ; rdfs:label "GSK-923295 [drugbank:DB06097]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB06097> . }